Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

203 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CPX-351 in FLT3-mutated acute myeloid leukemia.
Andrews C, Pullarkat V, Recher C. Andrews C, et al. Among authors: pullarkat v. Front Oncol. 2023 Nov 17;13:1271722. doi: 10.3389/fonc.2023.1271722. eCollection 2023. Front Oncol. 2023. PMID: 38044999 Free PMC article. Review.
Acute Lymphoblastic Leukemia in the Older Adult.
Aldoss I, Forman SJ, Pullarkat V. Aldoss I, et al. Among authors: pullarkat v. J Oncol Pract. 2019 Feb;15(2):67-75. doi: 10.1200/JOP.18.00271. J Oncol Pract. 2019. PMID: 30763199 Review.
Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia.
Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V. Aldoss I, et al. Among authors: pullarkat v. Am J Hematol. 2020 Oct;95(10):1193-1199. doi: 10.1002/ajh.25929. Epub 2020 Jul 28. Am J Hematol. 2020. PMID: 32628327 Free article.
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine.
Pratz KW, Jonas BA, Pullarkat V, Recher C, Schuh AC, Thirman MJ, Garcia JS, DiNardo CD, Vorobyev V, Fracchiolla NS, Yeh SP, Jang JH, Ozcan M, Yamamoto K, Illes A, Zhou Y, Dail M, Chyla B, Potluri J, Döhner H. Pratz KW, et al. Among authors: pullarkat v. J Clin Oncol. 2022 Mar 10;40(8):855-865. doi: 10.1200/JCO.21.01546. Epub 2021 Dec 15. J Clin Oncol. 2022. PMID: 34910556 Free PMC article. Clinical Trial.
Impact of FLT3 Mutation on Outcomes after Venetoclax and Azacitidine for Patients with Treatment-Naïve Acute Myeloid Leukemia.
Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, Kantarjian HM, DiNardo CD, Dail M, Duan Y, Chyla B, Potluri J, Miller CL, Wei AH. Konopleva M, et al. Among authors: pullarkat v. Clin Cancer Res. 2022 Jul 1;28(13):2744-2752. doi: 10.1158/1078-0432.CCR-21-3405. Clin Cancer Res. 2022. PMID: 35063965 Free PMC article.
WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.
Aribi A, Salhotra A, Afkhami M, Munteanu A, Ali H, Aldoss I, Otoukesh S, Al Malki MM, Sandhu KS, Koller P, Arslan S, Stewart F, Artz A, Curtin P, Ball B, O'Hearn J, Spielberger R, Smith E, Budde E, Nakamura R, Stein A, Forman S, Marcucci G, Becker PS, Pullarkat V. Aribi A, et al. Among authors: pullarkat v. Leuk Lymphoma. 2023 Nov-Dec;64(11):1811-1821. doi: 10.1080/10428194.2023.2241096. Epub 2023 Aug 3. Leuk Lymphoma. 2023. PMID: 37533373
203 results